Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed as Sector Perform by Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reaffirmed by research analysts at Royal Bank Of Canada in a report released on Tuesday, Benzinga reports. They currently have a $737.00 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective would suggest a potential downside of 1.52% from the company’s current price.

Other research analysts have also recently issued reports about the company. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Finally, Citigroup upped their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Fourteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $802.18.

Regeneron Pharmaceuticals Trading Down 0.5%

REGN stock traded down $3.88 during mid-day trading on Tuesday, hitting $748.37. 169,847 shares of the company were exchanged, compared to its average volume of 827,011. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The business has a fifty day simple moving average of $781.41 and a 200-day simple moving average of $720.99. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $859.34. The firm has a market capitalization of $77.05 billion, a P/E ratio of 18.46, a PEG ratio of 1.54 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the prior year, the firm earned $12.81 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the sale, the director directly owned 603 shares in the company, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the sale, the executive vice president owned 12,003 shares in the company, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,146 shares of company stock valued at $3,432,488 in the last three months. 6.97% of the stock is currently owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. State Street Corp grew its holdings in Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Franklin Resources Inc. grew its holdings in Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after acquiring an additional 106,861 shares in the last quarter. Nuveen LLC grew its holdings in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after acquiring an additional 835,240 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in Regeneron Pharmaceuticals by 7.2% during the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock worth $1,228,127,000 after acquiring an additional 106,632 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Biohaven entered a clinical supply agreement to evaluate its experimental cancer drug BHV-1530 in combination with Regeneron’s Libtayo in patients with solid tumors. Enrollment in the combination cohort is underway, creating potential long-term value for Libtayo and expanding Regeneron’s oncology pipeline. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is scheduled to report third-quarter results next month, making the upcoming earnings release a potential near-term catalyst. Investors will likely focus on Eylea sales, Libtayo momentum and management’s outlook. Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
• Negative Sentiment: Kodiak Sciences reported Phase 3 data showing its experimental eye-disease treatments achieved primary endpoints comparable to Eylea in wet age-related macular degeneration. The candidates were administered approximately every six months, versus Eylea’s roughly eight-week schedule, raising concerns that longer-lasting competitors could erode Eylea’s market share and pricing power. Kodiak Skyrockets on Positive Study Data
• Negative Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating but set a $737 price target, below the stock’s recent trading level. The cautious valuation signal adds to investor concerns despite Regeneron’s strong recent returns. Royal Bank of Canada Rating Update

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.